CellCept (mycophenolate mofetil) NDC 0004-0261

NDC codes

FDA NDC Directory

Product NDC (as listed)0004-0261Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00004-0261Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0004-0261-29	00004026129	1 BOTTLE, PLASTIC in 1 CARTON (0004-0261-29) / 225 mL in 1 BOTTLE, PLASTICMarketed from Oct 1, 1998

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): CellCept
Generic name (nonproprietary): mycophenolate mofetil
Active ingredients: Mycophenolate mofetil — 200 mg/mL
Dosage form: Powder, For suspension
Route: Oral
Labeler: Genentech, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 050759
Marketing start: Oct 1, 1998
Listing expires: Dec 31, 2027
Identifiers: Product ID 0004-0261_1e79ff42-b246-420f-96af-a7b8cbf6e76eSPL ID 1e79ff42-b246-420f-96af-a7b8cbf6e76eSPL set ID 37241e87-4af4-4dc3-a1aa-ea6f20d8dc40RxCUI 199058, 200060, 213394, 311880, 311881, 616435, 616444, 616447UNII UXH81S8ZVB, 9242ECW6R0
Pharmacologic class: Antimetabolite Immunosuppressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400004026129 followed by a unit qualifier and the quantity

Package 00004-0261-29. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Aug 5, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

CELLCEPT [mycophenolate mofetil (MMF)] is indicated for the prophylaxis of organ rejection, in adult and pediatric recipients 3 months of age and older of allogeneic kidney [see Clinical Studies (14.1) ], heart [see Clinical Studies (14.2) ] or liver transplants [see Clinical Studies (14.3) ] , in combination with other immunosuppressants. CELLCEPT is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)